Entero Healthcare [ENTERO] vs NOVELIX [NOVELIX] Detailed Stock Comparison

Entero Healthcare Solutions

NSE
Loading...

NOVELIX PHARMACEUTICALS LIMITE

BSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Entero Healthcare Solutions wins in 11 metrics, NOVELIX PHARMACEUTICALS LIMITE wins in 7 metrics, with 1 ties. Entero Healthcare Solutions appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Entero Healthcare Solutions NOVELIX PHARMACEUTICALS LIMITE Better
P/E Ratio (TTM) 48.93 48.76 NOVELIX PHARMACEUTICALS LIMITE
Price-to-Book Ratio 3.11 3.10 NOVELIX PHARMACEUTICALS LIMITE
Debt-to-Equity Ratio 24.63 0.00 Tie
PEG Ratio 5.72 0.17 NOVELIX PHARMACEUTICALS LIMITE
EV/EBITDA 28.71 39.81 Entero Healthcare Solutions
Profit Margin (TTM) 1.87% 1.41% Entero Healthcare Solutions
Operating Margin (TTM) 3.40% 2.65% Entero Healthcare Solutions
EBITDA Margin (TTM) 3.40% 2.65% Entero Healthcare Solutions
Return on Equity 5.36% 0.48% Entero Healthcare Solutions
Return on Assets (TTM) 3.51% 0.31% Entero Healthcare Solutions
Free Cash Flow (TTM) $-881.80M $-137.91M NOVELIX PHARMACEUTICALS LIMITE
1-Year Return -4.75% 181.69% NOVELIX PHARMACEUTICALS LIMITE
Price-to-Sales Ratio (TTM) 0.91 0.91 NOVELIX PHARMACEUTICALS LIMITE
Enterprise Value $58.10B $964.62M Entero Healthcare Solutions
EV/Revenue Ratio 0.97 0.75 NOVELIX PHARMACEUTICALS LIMITE
Gross Profit Margin (TTM) 10.11% 3.21% Entero Healthcare Solutions
Revenue per Share (TTM) $1,383 $85 Entero Healthcare Solutions
Earnings per Share (Diluted) $25.83 $1.13 Entero Healthcare Solutions
Beta (Stock Volatility) -0.79 0.50 Entero Healthcare Solutions

Entero Healthcare Solutions vs NOVELIX PHARMACEUTICALS LIMITE Stock Performance Analysis

Loading Price Chart...

ENTERO
NOVELIX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Entero Healthcare Solutions-1.26%0.29%-5.86%12.11%12.06%-0.64%
NOVELIX PHARMACEUTICALS LIMITE3.95%23.32%61.28%62.04%40.58%41.58%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Entero Healthcare Solutions-4.75%-1.12%-1.12%-1.12%-1.12%-1.12%
NOVELIX PHARMACEUTICALS LIMITE181.69%242.11%242.11%242.11%242.11%242.11%

Performance & Financial Health Analysis: Entero Healthcare Solutions vs NOVELIX PHARMACEUTICALS LIMITE

MetricENTERONOVELIX
Market Information
Market Cap i₹54.69B₹1.16B
Market Cap CategoryMid capSmall cap
10 Day Avg. Volume i76,0676,329
90 Day Avg. Volume i89,0936,508
Last Close₹1,122.40₹85.88
52 Week Range₹944.00 - ₹1,390.00₹29.33 - ₹88.40
% from 52W High-19.25%-2.85%
All-Time High₹1,584.25 (Nov 04, 2024)₹88.40 (Jun 15, 2026)
% from All-Time High-29.15%-2.85%
Growth Metrics
Quarterly Revenue Growth0.26%8.13%
Quarterly Earnings Growth0.09%5.79%
Financial Health
Profit Margin (TTM) i0.02%0.01%
Operating Margin (TTM) i0.03%0.03%
Return on Equity (TTM) i0.05%0.00%
Debt to Equity (MRQ) i24.630.00
Cash & Liquidity
Book Value per Share (MRQ)₹405.79₹17.77
Cash per Share (MRQ)₹37.37₹0.84
Operating Cash Flow (TTM) i₹-1,784,990,000₹-221,349,560
Levered Free Cash Flow (TTM) i₹948.20M₹845,200
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Entero Healthcare Solutions vs NOVELIX PHARMACEUTICALS LIMITE

MetricENTERO (Apr 24, 2026)NOVELIX (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i48.9348.76
Forward P/E i28.42N/A
PEG Ratio i5.720.17
Price to Sales (TTM) i0.910.91
Price to Book (MRQ) i3.113.10
Market Capitalization
Market Capitalization i₹54.69B₹1.16B
Enterprise Value i₹58.10B₹964.62M
Enterprise Value Metrics
Enterprise to Revenue i0.970.75
Enterprise to EBITDA i28.7139.81
Risk & Other Metrics
Beta i-0.790.50
Book Value per Share (MRQ) i₹405.79₹17.77

Financial Statements Comparison: Entero Healthcare Solutions vs NOVELIX PHARMACEUTICALS LIMITE

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricENTERO (2025)NOVELIX (2025)
Revenue/Sales i50.65B307.18M
Cost of Goods Sold i46.09B295.74M
COGS % of Revenue i91.0%96.3%
Gross Profit i4.56B11.45M
Gross Margin i9.0%3.7%
Research & Development iN/AN/A
Operating Income (EBIT) i1.42B1.12M
Operating Margin i2.8%0.4%
EBITDA i2.07B1.66M
EBITDA Margin i4.1%0.5%
Pre-Tax Income i1.39B1.23M
Pre-Tax Income % of Revenue i2.7%0.4%
Income Tax i313.05M388,230
Income Tax % of Revenue i0.6%0.1%
Net Income (Profit) i1.07B845,200
Profit Margin i2.1%0.3%

Balance Sheet & Liquidity Metrics

MetricENTERO (2025)NOVELIX (2025)
Cash & Equivalents i2.29B6.79M
Total Current Assets i20.76B269.33M
Total Current Assets % of Revenue i41.0%87.7%
Total Current Liabilities i8.45B96.67M
Total Current Liabilities % of Revenue i16.7%31.5%
Long-Term Debt i670.18M0
Long-Term Debt % of Revenue i1.3%0.0%
Total Shareholders Equity i17.70B175.39M
Retained Earnings i638.28M-18.76M
Retained Earnings % of Revenue i1.3%-6.1%
Property, Plant & Equipment i1.64B1.86M

Cash Flow Statement Comparison

MetricENTERO (2025)NOVELIX (2025)
Operating Cash Flow i-1.78B-221.35M
Operating Cash Flow % of Revenue i-3.5%-72.1%
Capital Expenditures i-103.73M-1.06M
Free Cash Flow i-881.80M-137.91M
FCF Margin i-1.7%-44.9%
Debt Repayment i-458.22MN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricENTERONOVELIX
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i43.51M21.09M
Float Shares i14.37M3.72M
% Held by Insiders i65.97%70.63%
% Held by Institutions i12.55%0.00%
% Held by Public i21.48%29.37%

Dividend Analysis & Yield Comparison: Entero Healthcare Solutions vs NOVELIX PHARMACEUTICALS LIMITE

MetricENTERONOVELIX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A